Möchten Sie immer auf dem neuesten Stand bleiben?

Anaveon announces presentation of positive ANV600 Clinical Data at ASCO 2026 and actively seeks partners for its legacy Oncology Portfolio.

Odyssey Therapeutics, Inc. announces pricing of its upsized IPO of 15,500,000 shares of its common stock at an IPO price of $18 per share.

Pharming today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS) in New Orleans, LA.

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 ...

This research investment will enable Dr. Jeanette Boudreau to prepare powerful natural killer cell immunotherapy to move into clinical trials

Oncolytics announced new data in metastatic colorectal cancer, demonstrating 3-4x improvement in duration response vs. historical 4-6 month benchmark.

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to...

Oncolytics Biotech announced Type C meeting with the FDA aligning on the design of clinical study to support approval of pelareorep in patients with SCAC.

EAACI, together with AEPNAA, SEAIC, and SEICAP, has called for urgent action to improve the safety of children at risk of anaphylaxis in schools.